RiverPark Advisors’s Pacira BioSciences PCRX Stock Holding History

RiverPark Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,132	Closed	-$866K	–	52
2018 Q4	$866K	Sell	20,132 -4,986	-20%	-$233K	0.38%	49
2018 Q3	$1.24M	Sell	25,118 -3,953	-14%	-$171K	0.3%	49
2018 Q2	$932K	Buy	29,071 +13,225	+83%	+$457K	0.19%	59
2018 Q1	$494K	Buy	+15,846	New	+$564K	0.1%	67
2017 Q4	–	Sell	-32,624	Closed	-$1.23M	–	77
2017 Q3	$1.23M	Hold	32,624	–	–	0.16%	66
2017 Q2	$1.56M	Hold	32,624	–	–	0.18%	61
2017 Q1	$1.49M	Hold	32,624	–	–	0.1%	60
2016 Q4	$1.05M	Hold	32,624	–	–	0.56%	53
2016 Q3	$1.12M	Hold	32,624	–	–	0.24%	52
2016 Q2	$1.1M	Hold	32,624	–	–	0.54%	52
2016 Q1	$1.73M	Buy	+32,624	New	+$1.91M	0.81%	44

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RiverPark Advisors's PCRX Position: Q1 2019 in Review

RiverPark Advisors sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 20,132 shares — an estimated $866K sold.

RiverPark Advisors first reported a position in PCRX in Q1 2016 and held it in 11 quarters. The position peaked at $1.73M in Q1 2016. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

RiverPark Advisors reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
RiverPark Advisors sold 20,132 Pacira BioSciences shares in Q1 2019, an estimated $866K.
RiverPark Advisors first reported a position in Pacira BioSciences in Q1 2016 and held it in 11 quarters.
RiverPark Advisors's Pacira BioSciences position peaked at $1.73M in Q1 2016.
210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on RiverPark Advisors's 13F filing for Q1 2019, filed 9 May 2019.